Literature DB >> 23893900

Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs.

Anastasia Ivanova1, Changfu Xiao.   

Abstract

Consider the problem of estimating a dose with a certain response rate. Many multistage dose-finding designs for this problem were originally developed for oncology studies where the mean dose-response is strictly increasing in dose. In non-oncology phase II dose-finding studies, the dose-response curve often plateaus in the range of interest, and there are several doses with the mean response equal to the target. In this case, it is usually of interest to find the lowest of these doses because higher doses might have higher adverse event rates. It is often desirable to compare the response rate at the estimated target dose with a placebo and/or active control. We investigate which of the several known dose-finding methods developed for oncology phase I trials is the most suitable when the dose-response curve plateaus. Some of the designs tend to spread the allocation among the doses on the plateau. Others, such as the continual reassessment method and the t-statistic design, concentrate allocation at one of the doses with the t-statistic design selecting the lowest dose on the plateau more frequently.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  continual reassessment method; group up-and-down designs; phase II trials; proof of concept; t-statistic design

Mesh:

Year:  2013        PMID: 23893900      PMCID: PMC3770738          DOI: 10.1002/pst.1585

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  13 in total

1.  Optimal designs for estimating the interesting part of a dose-effect curve.

Authors:  Frank Miller; Olivier Guilbaud; Holger Dette
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

2.  Adaptive Dunnett tests for treatment selection.

Authors:  Franz Koenig; Werner Brannath; Frank Bretz; Martin Posch
Journal:  Stat Med       Date:  2008-05-10       Impact factor: 2.373

3.  Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.

Authors:  Anastasia Ivanova; Se Hee Kim
Journal:  Biometrics       Date:  2008-05-13       Impact factor: 2.571

4.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

5.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

6.  Some practical improvements in the continual reassessment method for phase I studies.

Authors:  S N Goodman; M L Zahurak; S Piantadosi
Journal:  Stat Med       Date:  1995-06-15       Impact factor: 2.373

7.  Practical modifications of the continual reassessment method for phase I cancer clinical trials.

Authors:  D Faries
Journal:  J Biopharm Stat       Date:  1994-07       Impact factor: 1.051

8.  Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates.

Authors:  Changfu Xiao; Anastasia Ivanova
Journal:  J Stat Plan Inference       Date:  2012-07-01       Impact factor: 1.111

9.  Sequential designs for phase I clinical trials with late-onset toxicities.

Authors:  Y K Cheung; R Chappell
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

10.  A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.

Authors:  David B Hall; Ulrich Meier; Hans-Cristoph Diener
Journal:  Contemp Clin Trials       Date:  2005-03-28       Impact factor: 2.226

View more
  1 in total

1.  Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates.

Authors:  Changfu Xiao; Anastasia Ivanova
Journal:  J Stat Plan Inference       Date:  2012-07-01       Impact factor: 1.111

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.